"The pharma industry's approach to aging certainly counts as long over due for innovation," O'Neill said, citing regulatory controls as an obstacle. That viewpoint is not unlike that of Thiel, who reiterated to the New York Times this week: "Science is technology's older brother who has fallen on hard times ... I have some strong opinions on this....